CD274 and neoplasm: Our study showed that niraparib could regulate the tumor immune microenvironment in cervical cancer, and when combined with PD-L1 monoclonal antibody in vivo, the inhibitory effect was significantly better than either monotherapy, which provided a solid theoretical basis for the treatment of metastatic or recurrent cervical cancer with PARPi combined with PD-L1 blockade.